Apogee Therapeutics presented significant updates across its pipeline at its inaugural Virtual R&D Day, highlighting progress for its novel biologic programs in inflammatory and immunology diseases. The company reported positive interim Phase 1 data for APG808, an anti-IL4Rα antibody, which was well-tolerated and demonstrated an approximate 55-day half-life. This profile supports potential two- to three-month dosing, a five-fold increase compared to DUPIXENT's bi-weekly regimen.
Further data up to 12 months for APG777, an anti-IL13 antibody, reinforced its potential for best-in-class efficacy and dosing, including a 77-day half-life that could enable annual dosing. Based on strong enrollment, the 16-week topline data from the APG777 Phase 2 Part A trial in atopic dermatitis has been accelerated to mid-2025. This acceleration indicates strong operational execution and potential enthusiasm from investigators and patients.
Apogee also detailed its combination therapy strategy, announcing preclinical and coformulation proof-of-concept for APG777 + APG990. A Phase 1b head-to-head trial against DUPIXENT is expected to initiate in 2025, with data anticipated in the second half of 2026. Additionally, preclinical proof-of-concept was achieved for the APG777 + APG333 combination in asthma and COPD, with clinical trial planning underway.
The company plans to commence a Phase 1 trial for APG333, an anti-TSLP antibody, by the end of 2024, with interim data expected in the second half of 2025. These updates collectively underscore Apogee's commitment to developing differentiated therapies with enhanced dosing convenience and broader efficacy across multiple I&I indications.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.